Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
drug prices
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
opioid
2
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
2
×
san francisco top stories
seattle blog main
2
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
abbvie
activism
acute hepatic porphyria
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
alnylam pharmaceuticals
What
approval
2
×
bio
drug
2
×
roundup
advanced
alnylam’s
bff
biogen’s
biopharmaceutical
companies
conference
convo
deals
devoted
disease
earlier
easl
failures
form
gene
kicked
littered
liver
major
nash
new
news
price
race
remains
road
strategy
talk
therapy
treat
updates
world's
Language
Current search:
opioid
×
" seattle blog main "
×
drug
×
" san francisco blog main "
×
approval
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More